V. Stojsic, “Real World Data Survival Outcomes of First Line Immunotherapy with Pembrolizumab in High Expressers with stage IV Non-Small Cell Lung Cancer”, Radiol Oncol, vol. 60, no. 3, pp. 450–458, Sep. 2026.